查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919397

人工智慧医学影像软体市场－肺炎诊断（按模式、部署类型、应用程式和最终用户划分）－2026-2032年全球预测

AI Medical Imaging Software for Pneumonia Market by Modality, Deployment, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，用于肺炎诊断的 AI 医学影像软体市场规模将达到 12.3 亿美元，到 2026 年将成长至 13.1 亿美元，到 2032 年将达到 25.4 亿美元，复合年增长率为 10.85%。

关键市场统计数据
基准年 2025 12.3亿美元
预计年份：2026年 13.1亿美元
预测年份 2032 25.4亿美元
复合年增长率 (%) 10.85%

一份清晰实用的人工智慧医学影像肺炎诊疗实施指南，概述了该技术、临床预期、监管压力和实施现实。

用于肺炎诊断的人工智慧影像分析技术已不再是实验性辅助手段，而是成熟且实用的工具集，广泛应用于第一线临床诊疗、放射科工作流程和医疗系统策略。演算法效能、计算效率和整合框架的最新进展拓展了其应用范围，从急诊现场的初步分诊到疾病进展的自动监测，均可胜任。同时，低剂量CT通讯协定的改进和更精细的影像预处理技术提高了机器学习模型可获得的讯号质量，从而增强了诊断的可靠性。

推动人工智慧医学影像在肺炎诊断领域变革的关键转折点强调技术成熟度、协作性、可解释性和工作流程整合。

在模型架构改进、资料可用性提升以及系统级效率需求的推动下，医学影像领域的人工智慧格局正在经历一场变革。从架构层面来看，新的深度学习方法和自我监督预训练范式提高了模型对领域变化的稳健性，并增强了模型在不同扫描仪类型和患者群体间的泛化能力。这些演算法的改进，加上边缘和云端运算能力的日益普及，使得在不影响临床吞吐量的前提下，实现近乎即时的推理成为可能。

评估不断变化的关税政策将如何重塑人工智慧驱动的肺炎成像解决方案的采购选择、供应链和部署策略。

关税政策和贸易趋势的变化可能对医疗影像硬体、云端运算资源以及支援人工智慧部署的整合软体解决方案的供应链产生重大影响。新增或调整后的关税可能会影响先进CT和X光硬体的组件价格，改变云端运算与本地部署运算的相对经济效益，并影响供应商关于其解决方案组件的生产或託管地点的决策。这些趋势促使供应商和医疗系统重新评估筹资策略、服务本地化以及与维护和软体更新相关的合约条款。

深度细分洞察将模式、终端用户环境、整合方法、部署架构和应用案例与临床价值连结起来。

这种分割方法为理解价值创造的领域以及临床工作流程如何与技术选择相互作用提供了一个实用的框架。依影像方式划分，分割包括电脑断层扫描、MRI、超音波和X射线，其中CT进一步细分为高解析度CT和低剂量CT。这些影像方式的选择会影响诊断灵敏度、辐射暴露的考量以及人工智慧能够最大程度发挥临床价值的领域。具有更高原始解析度的成像方式通常允许进行更详细的演算法分析，而低剂量方法则需要对低信噪比具有稳健性的模型。

区域洞察：揭示临床重点、管理体制和基础设施现状将如何对世界不同地区人工智慧成像技术的应用产生不同的影响

地理因素影响人工智慧影像解决方案的临床优先事项、监管预期、采购惯例和竞争格局。在美洲，医疗服务提供者通常优先考虑那些能够快速诊断、与各种电子健康记录 (EHR) 系统整合以及与现有 PACS 基础设施互通性的解决方案，而创新丛集和学术机构则进一步推动早期临床检验和试验计画。该地区也倾向于强调围绕人工智慧应用开展的以结果为导向的讨论和组织管治。

主要企业级洞察侧重于证据生成、互通性、整合伙伴关係和营运支持，以确定竞争优势。

在这个领域，竞争地位取决于临床检验、技术互通性以及与医疗系统和影像供应商的市场推广关係。主要企业凭藉深厚的临床证据基础、强大的PACS和EHR系统整合工具包以及支援异质部署的营运能力脱颖而出。与影像硬体製造商和云端服务供应商的伙伴关係，透过简化整合和加快客户价值实现速度，强化了产品提案。

结合多站点检验、灵活整合、绩效监控管治以及相关人员之间的协作，并为领导者提供具体建议。

行业领导者应优先考虑将严谨的临床检验与切实可行的整合策略以及清晰的持续性能管理管治相结合的方法。首先，应投资进行涵盖不同扫描仪类型和患者群体的多中心检验，以证明其可重复性并发现可能影响临床安全的极端情况。同时，应进行前瞻性可用性研究，以记录真实工作流程中的互动和临床医师信心指标。

一项综合调查方法，结合了相关人员访谈、技术分析、监管审查和竞争对手分析，并明确了其局限性。

本分析的研究基础是整合了对关键相关人员的访谈、技术文献、监管申报文件和产品文檔，从而建构了人工智慧成像技术在肺炎诊断中的多角度观点。关键资讯来源包括与放射科医生、急诊医生、影像技师、IT主管和采购负责人的结构化讨论，以了解实际应用中的限制因素和推动技术应用的因素。这些定性研究结果与同行评审的研究文章、白皮书和已发布的监管核准进行了三角验证，以评估技术声明和临床证据。

总结全文，阐述检验、互通性、模组化实施和管治将如何决定人工智慧成像的临床部署和营运影响。

用于肺炎诊断的人工智慧影像分析技术已从设想阶段迈向实际应用阶段，但其最终影响将取决于相关人员如何妥善解决互通性、检验和营运管治等问题。成功的临床应用取决于能否证明其在不同显像模式和医院环境中的可重复性，以及如何与现有工作流程和IT限制整合。当这些要素协调一致时，人工智慧可以缩短诊断流程，支援标准化报告生成，并加强疾病进展监测。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 肺炎诊断人工智慧医学影像软体市场（以影像方式划分）

  • 电脑断层扫描
    • 高解析度CT
    • 低剂量CT
  • MRI
  • 超音波
  • X射线

9. 肺炎诊断人工智慧医学影像软体市场（按部署方式划分）

  • 云
    • 混合云端
    • 私有云端
    • 公共云端
  • 本地部署

第十章 肺炎诊断人工智慧医学影像软体市场（按应用领域划分）

  • 侦测
    • 确诊
    • 初步筛检
  • 监测
  • 分诊
  • 工作流程自动化

第十一章 肺炎诊断人工智慧医学影像软体市场（按最终用户划分）

  • 诊所
  • 诊断影像中心
  • 医院
    • 急诊室
    • 放射科

第十二章 各地区用于肺炎诊断的人工智慧医学影像软体市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 肺炎诊断人工智慧医学影像软体市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国用于肺炎诊断的人工智慧医学影像软体市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国人工智慧医疗影像软体市场在肺炎诊断的应用

第十六章 中国用于肺炎诊断的人工智慧医学影像软体市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aidoc Medical Ltd.
  • Arterys, Inc.
  • Butterfly Network, Inc.
  • Canon Medical Systems Corporation
  • Caption Health, Inc.
  • Enlitic, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • IBM Corporation
  • Koninklijke Philips NV
  • Lunit Inc.
  • NVIDIA Corporation
  • Qure.ai Technologies Pvt. Ltd.
  • RadNet, Inc.
  • Samsung Electronics Co., Ltd
  • Siemens Healthineers AG
  • Viz.ai, Inc.
  • Zebra Medical Vision Ltd.
Product Code: MRR-F14BA1B34302

The AI Medical Imaging Software for Pneumonia Market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.31 billion in 2026, with a CAGR of 10.85%, reaching USD 2.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.23 billion
Estimated Year [2026] USD 1.31 billion
Forecast Year [2032] USD 2.54 billion
CAGR (%) 10.85%

A clear and pragmatic introduction to AI medical imaging for pneumonia that outlines technology, clinical expectations, regulatory pressures and implementation realities

AI-enabled imaging for pneumonia is no longer an experimental adjunct; it has matured into a practical toolset that intersects frontline clinical care, radiology workflows, and health system strategy. Recent advances in algorithmic performance, compute efficiency, and integration frameworks have widened the range of feasible use cases, from initial triage in emergency settings to automated monitoring of disease progression. In parallel, improvements in low-dose CT protocols and more nuanced image pre-processing have strengthened the signal quality available to machine learning models, improving diagnostic reliability.

Clinical stakeholders now expect AI solutions to offer transparent decision support that complements radiologist interpretation, reduces time-to-diagnosis, and supports standardized reporting. Health systems emphasize interoperability with electronic health records and picture archiving systems to avoid workflow disruption. Regulators and payers are increasing scrutiny on safety, reproducibility, and evidence of clinical utility, shaping product development roadmaps and deployment choices. Consequently, developers and healthcare leaders must reconcile rapid technological innovation with pragmatic implementation constraints and patient safety concerns.

As adoption conversations progress, organizations should view AI for pneumonia imaging as a socio-technical challenge rather than a purely technical one. Successful initiatives balance algorithmic rigor with clinician engagement, validation across diverse patient cohorts, and clear governance for performance monitoring. This introductory perspective frames the subsequent sections that examine transformational shifts, tariff impacts, segmentation, regional dynamics, competitive positioning, practical recommendations, and the rigors of the underlying research approach.

Key transformative shifts shaping AI medical imaging for pneumonia that emphasize technical maturation, federated collaboration, explainability, and workflow integration

The landscape for AI in medical imaging is undergoing transformative shifts driven by improvements in model architectures, data availability, and system-level demands for efficiency. Architecturally, novel deep learning approaches and self-supervised pretraining paradigms have enhanced robustness to domain shifts, enabling models to better generalize across scanner types and patient populations. These algorithmic improvements have been matched by more accessible compute at the edge and in the cloud, permitting near real-time inference without compromising clinical throughput.

At the same time, data governance and federated learning approaches are reshaping how institutions contribute to model training without relinquishing raw patient data, which accelerates collaborative validation while maintaining privacy. This trend dovetails with increasing expectations for explainability and auditability, prompting vendors to embed interpretability modules and confidence estimates that clinicians can interrogate during decision-making.

Operationally, there is a palpable shift from proof-of-concept pilots to sustained clinical deployment, necessitating robust change management, continuous performance monitoring, and integration with existing radiology information systems. Payers and health systems are also re-evaluating reimbursement frameworks and care pathways to reflect AI's role in triage and monitoring. Taken together, these trends signal a maturation phase in which technical advances are increasingly evaluated through the lens of clinical workflow fit, patient safety, and measurable improvements in care delivery.

Assessment of how evolving tariff policies reshape procurement choices, supply chains, and deployment strategies for AI-enabled pneumonia imaging solutions

Tariff policy changes and trade dynamics can materially influence the supply chain for medical imaging hardware, cloud compute resources, and integrated software solutions that underpin AI deployments. New or adjusted tariffs affect component pricing for advanced CT and X-ray hardware, alter the relative economics of cloud-based versus on-premises compute, and can influence decisions about where vendors manufacture or host components of their solutions. These dynamics prompt both vendors and health systems to reassess procurement strategies, localization of services, and contractual terms related to maintenance and software updates.

Institutions may respond by increasing emphasis on modular architectures that allow selective substitution of regional suppliers or by negotiating longer-term service agreements that hedge against sudden cost shifts. In addition, public-sector procurement bodies and health system procurement offices may prioritize suppliers with established local manufacturing or hosting footprints to minimize exposure to tariff volatility. From a clinical standpoint, the focus remains on ensuring continuity of service, validated performance across equipment variants, and reliable support that spans hardware and software domains.

Finally, tariff-driven supply chain shifts can accelerate cloud adoption where compute and software licensing can be contracted independently from hardware sourcing, or conversely, drive investments in on-premises capacity when cross-border costs become prohibitive. The net effect is a recalibration of deployment decisions, vendor relationships, and capital allocation, reinforcing the need for flexible integration strategies and contractual safeguards that anticipate trade policy variability.

Deep segmentation insights connecting modality, end-user environments, integration approaches, deployment architectures and application use cases to clinical value

Segmentation offers a practical framework for understanding where value is captured and how clinical workflows interact with technology choices. By modality, the field encompasses CT scan, MRI, ultrasound, and X-ray, with CT further distinguished between high-resolution CT and low-dose CT; these modality choices influence diagnostic sensitivity, radiation exposure considerations, and where AI can add the most clinical value. Modalities with higher native resolution typically enable more granular algorithmic analyses, while low-dose approaches require models that are robust to lower signal-to-noise ratios.

When considering end users, providers range from clinics to diagnostic imaging centers and hospitals, where hospitals are further differentiated into emergency departments and radiology departments. Emergency department deployments prioritize rapid triage and integration with acute workflows, whereas radiology departments focus on diagnostic confirmation, standardized reporting, and throughput optimization. The same solution may need different interfaces and validation strategies depending on whether it is used in a high-volume imaging center or an inpatient radiology service.

Integration pathways include electronic health record integration, PACS integration, and standalone deployments, with PACS integration subdivided into cloud PACS and local PACS. Integration choices affect data flows, latency, and the operational burden of software maintenance. Deployment models span cloud and on-premises, where cloud options may be further segmented into hybrid cloud, private cloud, and public cloud architectures. Each deployment model carries trade-offs related to data residency, scalability, and management overhead.

Finally, application-level segmentation covers detection, monitoring, triage, and workflow automation, with detection further differentiated between diagnostic confirmation and initial screening. These application categories map to distinct clinical value propositions: initial screening and triage aim to accelerate identification and patient routing, while diagnostic confirmation and monitoring support clinical decision-making over the course of care. Effective product strategies align modality, end-user workflows, integration pattern, deployment environment, and the primary clinical application to create coherent value propositions that meet both technical and operational constraints.

Regional intelligence that highlights how clinical priorities, regulatory regimes, and infrastructure realities differentially influence AI imaging adoption across global regions

Geographic dynamics shape clinical priorities, regulatory expectations, procurement practices, and the competitive landscape for AI imaging solutions. In the Americas, healthcare providers often prioritize fast time-to-diagnosis, integration with diverse EHR ecosystems, and solutions that demonstrate interoperability with existing PACS infrastructure; innovation clusters and academic centers further drive early clinical validation and pilot programs. This region typically emphasizes outcomes-based conversations and institutional governance for AI adoption.

Europe, Middle East & Africa presents a heterogeneous regulatory and clinical environment where data protection frameworks, decentralized health systems, and diverse infrastructure maturity levels influence deployment patterns. Vendors often need region-specific compliance pathways, multilingual user experiences, and adaptable training datasets to ensure robust performance across populations. Health ministries and national procurement bodies may also exert greater influence over purchasing decisions and standards for clinical evidence.

Asia-Pacific is characterized by a mix of high-volume tertiary centers, rapidly digitizing community hospitals, and technology-savvy private providers. This region often leverages local manufacturing and vendor partnerships to accelerate deployment, while also navigating variable regulatory timelines and differing expectations for cloud adoption. Across all regions, local clinical validation, clinician engagement, and the ability to align with regional procurement policies remain decisive factors in adoption, with strategies calibrated to the unique operational realities of each geography.

Key company-level insights focusing on evidence-generation, interoperability, integration partnerships, and operational support that determine competitive advantage

Competitive positioning in this field is shaped by the confluence of clinical validation, technical interoperability, and go-to-market relationships with health systems and imaging vendors. Leading companies differentiate through deep clinical evidence, strong integration toolkits for PACS and EHR systems, and the operational capacity to support heterogeneous deployments. Partnerships with imaging hardware manufacturers and cloud providers strengthen product propositions by simplifying integration and reducing time-to-value for customers.

Smaller innovators often focus on niche applications or modality-specific solutions, using clinical partnerships to demonstrate utility in targeted workflows such as emergency triage or automated monitoring. Meanwhile, larger vendors leverage established relationships with health systems to pilot multi-site rollouts and to offer bundled solutions that include software, deployment services, and ongoing performance monitoring. The ability to deliver transparent validation studies, post-deployment monitoring, and clinically interpretable outputs is increasingly a baseline expectation rather than a point of differentiation.

Regulatory clearances and real-world evidence programs are critical competitive assets; companies that invest in robust clinical trials and post-market surveillance can more credibly address safety and efficacy concerns. Strategic alliances with regional integrators and compliance partners further enable market entry and sustained adoption in complex healthcare environments. Ultimately, differentiation rests on aligning product design with clinician workflows, ensuring reproducible performance across devices and populations, and offering operational support that reduces the friction of clinical deployment.

Actionable recommendations for leaders that combine multi-site validation, flexible integration, governance for performance monitoring, and stakeholder alignment

Industry leaders should prioritize an approach that combines rigorous clinical validation with pragmatic integration strategies and clear governance for ongoing performance management. First, invest in multi-institutional validation across diverse scanner types and patient cohorts to demonstrate reproducibility and to uncover edge cases that could impact clinical safety. Complement these efforts with prospective usability studies that capture real-world workflow interactions and clinician trust metrics.

Second, build integration flexibility into product architectures so that solutions can operate within EHR-integrated, PACS-integrated (both cloud and local), or standalone environments. This reduces adoption friction and enables health systems to choose deployment models-hybrid cloud, private cloud, public cloud, or on-premises-that align with their data residency and operational preferences. Design for modularity so hardware or software components can be swapped without extensive revalidation.

Third, establish transparent post-deployment governance and monitoring frameworks that include automated performance drift detection, clinician feedback loops, and scheduled revalidation protocols. Such governance should be paired with clear documentation, interpretability features, and mechanisms for clinicians to override or annotate algorithmic outputs. Finally, engage procurement, clinical leadership, and IT early in pilots to align success metrics, contractual terms, and support models, ensuring that technical innovation translates into sustained clinical impact.

Comprehensive research methodology integrating stakeholder interviews, technical analysis, regulatory review, and competitive profiling with transparent limitations

The research underpinning this analysis synthesizes primary stakeholder interviews, technical literature, regulatory filings, and product documentation to create a multi-dimensional view of AI imaging for pneumonia. Primary inputs included structured discussions with radiologists, emergency physicians, imaging technologists, IT leaders, and procurement officers to capture real-world constraints and adoption drivers. These qualitative insights were triangulated with a review of peer-reviewed studies, white papers, and public regulatory approvals to assess technical claims and clinical evidence.

Technical assessments examined algorithmic methodologies, model explainability features, robustness to domain shift, and integration capabilities with PACS and EHR systems. Deployment considerations evaluated cloud versus on-premises architectures, data residency requirements, and the operational burden of software lifecycle management. Competitive analysis drew on product roadmaps, partnership announcements, and documented case studies to profile vendor strengths and common go-to-market approaches.

Limitations of the methodology include potential selection bias in interview subjects and the variability of publicly available clinical evidence. To mitigate these risks, sources from multiple healthcare systems and geographic regions were consulted, and findings emphasize cross-cutting themes rather than granular performance metrics. The approach prioritizes actionable, implementation-focused intelligence suited to clinical leaders, procurement teams, and technology strategists.

A concluding synthesis that distills how validation, interoperability, modular deployment and governance determine the clinical trajectory and operational impact of AI imaging

AI-enabled imaging for pneumonia has moved from promise to practical utility, yet its ultimate impact will depend on how well stakeholders address interoperability, validation, and operational governance. Clinical adoption hinges on demonstrable reproducibility across imaging modalities and institutional contexts, combined with integration that respects existing workflows and IT constraints. When these elements align, AI can shorten diagnostic pathways, support standardized reporting, and enhance monitoring of disease progression.

Conversely, solutions that neglect rigorous validation, fail to integrate cleanly with PACS and EHR systems, or lack robust post-deployment monitoring risk limited uptake and clinician resistance. The most promising pathways center on modular architectures, multi-site evidence generation, and partnerships that bridge clinical, technical, and procurement domains. By focusing on these priorities, developers and provider organizations can convert technological capability into measurable clinical and operational value.

In summary, the trajectory for AI in pneumonia imaging favors solutions that combine technical excellence with pragmatic deployment models and transparent governance. Stakeholders that invest in these dimensions will be best positioned to realize the benefits of improved diagnostic consistency, streamlined workflows, and better-aligned clinical decision support.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. AI Medical Imaging Software for Pneumonia Market, by Modality

  • 8.1. Ct Scan
    • 8.1.1. High Resolution CT
    • 8.1.2. Low Dose CT
  • 8.2. Mri
  • 8.3. Ultrasound
  • 8.4. X Ray

9. AI Medical Imaging Software for Pneumonia Market, by Deployment

  • 9.1. Cloud
    • 9.1.1. Hybrid Cloud
    • 9.1.2. Private Cloud
    • 9.1.3. Public Cloud
  • 9.2. On Premises

10. AI Medical Imaging Software for Pneumonia Market, by Application

  • 10.1. Detection
    • 10.1.1. Diagnostic Confirmation
    • 10.1.2. Initial Screening
  • 10.2. Monitoring
  • 10.3. Triage
  • 10.4. Workflow Automation

11. AI Medical Imaging Software for Pneumonia Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
    • 11.3.1. Emergency Department
    • 11.3.2. Radiology Department

12. AI Medical Imaging Software for Pneumonia Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. AI Medical Imaging Software for Pneumonia Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. AI Medical Imaging Software for Pneumonia Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States AI Medical Imaging Software for Pneumonia Market

16. China AI Medical Imaging Software for Pneumonia Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aidoc Medical Ltd.
  • 17.6. Arterys, Inc.
  • 17.7. Butterfly Network, Inc.
  • 17.8. Canon Medical Systems Corporation
  • 17.9. Caption Health, Inc.
  • 17.10. Enlitic, Inc.
  • 17.11. Fujifilm Holdings Corporation
  • 17.12. GE HealthCare Technologies Inc.
  • 17.13. IBM Corporation
  • 17.14. Koninklijke Philips N.V.
  • 17.15. Lunit Inc.
  • 17.16. NVIDIA Corporation
  • 17.17. Qure.ai Technologies Pvt. Ltd.
  • 17.18. RadNet, Inc.
  • 17.19. Samsung Electronics Co., Ltd
  • 17.20. Siemens Healthineers AG
  • 17.21. Viz.ai, Inc.
  • 17.22. Zebra Medical Vision Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HIGH RESOLUTION CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HIGH RESOLUTION CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HIGH RESOLUTION CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY LOW DOSE CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY LOW DOSE CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY LOW DOSE CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY ON PREMISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY ON PREMISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY ON PREMISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DIAGNOSTIC CONFIRMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DIAGNOSTIC CONFIRMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DIAGNOSTIC CONFIRMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY INITIAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY INITIAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY INITIAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY TRIAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY TRIAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY TRIAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY WORKFLOW AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY WORKFLOW AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY WORKFLOW AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY RADIOLOGY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY RADIOLOGY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY RADIOLOGY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 162. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 163. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 164. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 189. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 190. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 191. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 198. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 199. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 200. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NATO AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CT SCAN, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA AI MEDICAL IMAGING SOFTWARE FOR PNEUMONIA MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)